Metronidazole has been the standard treatment for Bacterial Vaginosis over 30 years. During these years new insights regarding the nature, extent and risks in the field of Bacterial Vaginosis have been obtained.
Unlike 30 years ago Bacterial Vaginose often no longer consists of just Gardnerella Vaginalis. Other anaerobic bacteria, such as Prevotella, Mobilincus and Atopobium Vaginae, play an important role in Bacterial Vaginoses and in combination with resistance development make treatment more complicated. Areobe Vaginitis (Streptococci, Staphylococci Areus, E.coli) or a fungal infection also play a role in Bacterial Vaginosis.
It has recently been demonstrated that particularly Gardnerella Vaginalis and Atopobium Vaginae produce a thick bio-film to the vaginal epithelium this protects the bacteria against treatments with antibiotics. Antibiotics hardly penetrate into this bio-film, which means that the bacteria keep recovering and this leads to recurrent infections. In addition, antibiotic use develops resistant forms in this bio-film.
Evagynal a broad spectrum antiseptic that has an excellent effect on almost all pathogens involved in gynecological infections, due to its unique composition. Evagynal very effective against bio-film formation.
In a comparative study of 110 patients, 86.7% of patients were still free of Bacterial Vaginosis 3 weeks after monodose treatment with Evagynal. Evagynal only has a small number of local side effects.
The broad effect of Evagynal on pathogens, the excellent tolerance, the monodose application and extremely low chance of developing resistance make Evagynal a first choice in the treatment in Bacterial Vaginosis compared to metronidazole.
- Polyhexamethylene Biguanide
- Sodium edetate
- Hydroxyethyl cellulose
- Lactic acid
- Aqua purificata
Evagynal® vaginal solution
Z-Index number: 15792005
Pharmacy Purchase price ex. VAT: € 9.62
Consumer Price incl. VAT: € 13.97